JP2015502389A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502389A5
JP2015502389A5 JP2014548078A JP2014548078A JP2015502389A5 JP 2015502389 A5 JP2015502389 A5 JP 2015502389A5 JP 2014548078 A JP2014548078 A JP 2014548078A JP 2014548078 A JP2014548078 A JP 2014548078A JP 2015502389 A5 JP2015502389 A5 JP 2015502389A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition according
stroke
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548078A
Other languages
English (en)
Japanese (ja)
Other versions
JP6127063B2 (ja
JP2015502389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076691 external-priority patent/WO2013093027A1/en
Publication of JP2015502389A publication Critical patent/JP2015502389A/ja
Publication of JP2015502389A5 publication Critical patent/JP2015502389A5/ja
Application granted granted Critical
Publication of JP6127063B2 publication Critical patent/JP6127063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548078A 2011-12-22 2012-12-21 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用 Active JP6127063B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254.5 2011-12-22
EP11195254 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (3)

Publication Number Publication Date
JP2015502389A JP2015502389A (ja) 2015-01-22
JP2015502389A5 true JP2015502389A5 (enExample) 2016-02-12
JP6127063B2 JP6127063B2 (ja) 2017-05-10

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548078A Active JP6127063B2 (ja) 2011-12-22 2012-12-21 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用

Country Status (10)

Country Link
US (1) US9452203B2 (enExample)
EP (1) EP2793935B1 (enExample)
JP (1) JP6127063B2 (enExample)
KR (1) KR102022231B1 (enExample)
CN (1) CN104080474B (enExample)
AU (1) AU2012318275B2 (enExample)
CA (1) CA2858984C (enExample)
DK (1) DK2793935T3 (enExample)
ES (1) ES2587863T3 (enExample)
WO (1) WO2013093027A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
PL2914291T3 (pl) 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
ME03326B (me) 2013-03-15 2019-10-20 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
PL3280440T3 (pl) 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
WO2017087882A1 (en) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
DK1965831T3 (da) * 2005-12-21 2011-10-24 Pharming Intellectual Pty Bv Anvendelse af C1-inhibitor til forebyggelse af iskæmi-reperfusionsskade
SI2380587T1 (en) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury

Similar Documents

Publication Publication Date Title
JP2022031772A5 (enExample)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2015518818A5 (enExample)
JP2013533858A5 (enExample)
JP2016539946A5 (enExample)
JP2015517488A5 (enExample)
FI4374873T3 (fi) Aine käytettäväksi silmäsairauksien hoidossa tai ehkäisyssä
JP2016516073A5 (enExample)
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP2016514132A5 (enExample)
JP2015514115A5 (enExample)
JP2016508123A5 (enExample)
JP2018521643A5 (enExample)
JP2017533972A5 (enExample)
JP2018509388A5 (enExample)
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
JP2020520916A5 (enExample)
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
HK1255481A1 (zh) 用於治疗hcv的方法
JP2015524823A5 (enExample)
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
JP2017524721A5 (enExample)